Navigation Links
XBiotech Expands Portfolio to Include Biosimilars
Date:2/26/2013

AUSTIN, Texas, Feb. 26, 2013 /PRNewswire/ -- XBiotech, a privately held biotechnology company, announced today that it is entering the biosimilar business. The Company is launching its biosimilar business with development of two of the world's leading therapeutic antibodies, one an oncology and the other an anti-inflammatory product. Entering into the biosimilar space will complete what XBiotech considers is its strategic portfolio of therapeutic antibodies. The Company believes that its manufacturing technology will lower production costs for biological products by an order of magnitude compared to other developers of generic biologics. Moreover, the Company claims that the flexibility and short lead-times needed to build production capacity is ideally suited for addressing the uncertain market conditions for biosimilars. The Company aims to enter into clinical trials with its first biosimilar product within the next year and launch into the market place by 2017.

(Logo: http://photos.prnewswire.com/prnh/20121017/MM95359LOGO)

"With our ability to manufacture antibody product at ultra-low costs, our aim is to make XBiotech the most competitive provider of biosimilar products in the world," said John Simard , president and CEO of XBiotech. "This is a logical next step to round out our antibody assets and fully exploit XBiotech's antibody commercialization platform."

There are a number of different biosimilar antibodies expected to hit the market beginning in 2014, including generic versions of Avastin®, Herceptin®, Remicade™, Rituxan®, and others.  These therapeutics currently represent the majority of revenues from global sales of antibodies, of more than $40 billion.  The potential to capture significant share of this market is luring a number of players, including heavy-weight producers of branded biologics, such as Amgen, and diverse entrants, such as Samsung, into the biosimilar development. However, with the large number of developers there remains considerable uncertainty about how market share is going to be divided, once a number of competing products hit the market.

Simard added that "In the biosimilar space cost competitiveness is going to be crucial to the success of these products. Market share is going to be driven by the ability to provide these products to the end user at lower costs than the competitor's. Developers capable of dramatically reducing cost of goods and establishing innovative distribution strategies will ultimately be able to dominate the biosimilar market. We believe XBiotech is well positioned to take advantage of this opportunity."

About XBiotech
XBiotech is pioneering breakthrough therapies that improve the safety and efficacy of antibody therapeutics. The Company's lead product candidate inhibits chronic sterile inflammation by targeting IL-1α, a master regulator of inflammation. The clinical development program addresses tremendous unmet medical need in multiple disease indications including, acne, psoriasis, cachexia, cancer, type 2 diabetes and cardiovascular disease. XBiotech is also revolutionizing scalable, flexible manufacturing systems for the production of biological therapies.  Using minimal infrastructure and disposable bioreactor technology – to dramatically reduce capital requirements, operating complexity, and lead times - the Company has established a compelling commercialization path for therapeutic antibodies.  For more information on how XBiotech is advancing human monoclonal antibody therapy please visit www.xbiotech.com.

Contact: 
Investors: 
Erika Geimonen
XBiotech
info@xbiotech.com
512.386.2906
Media:
Aaron DeLucia
Porter Novelli
aaron.delucia@porternovelli.com
512.241.2249


'/>"/>
SOURCE XBiotech
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. XBiotech Announces Positive Phase II Clinical Trial Results for Lead Candidate MABp1 in Acne Vulgaris
2. RF Technologies expands product offering with RTLS
3. Life Technologies Acquires BAC BV, Expands Capabilities in Bioprocessing
4. Superlift Expands Line of Stainless Steel Powered Pallet Trucks
5. UMBC Expands Offerings at The Universities at Shady Grove with Biotechnology Graduate Program
6. 1DegreeBio Expands its Product Review Platform Across Life Sciences
7. Genuine Bio-Fuel Inc. Expands Operations to Puerto Rico
8. Rhythm Expands Series B Financing to $33 Million; Adds Pfizer Ventures as an Investor
9. H3 Biomedicine Expands Cambridge Facilities, Doubles Employee Base as Scientific Program Advances
10. Medical Marijuana, Inc. Portfolio Company CanChew BioTechnologies Inc. Updates and Expands Free Product Trial
11. Why Texas is #1 in Business: Local BioTech Company Expands
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... , ... October 10, 2017 , ... Dr. Bob Harman, ... his local San Diego Rotary Club. The event entitled “Stem Cells ... and had 300+ attendees. Dr. Harman, DVM, MPVM was joined by two human ...
(Date:10/10/2017)... ... October 10, 2017 , ... The Pittcon Program Committee ... honoring scientists who have made outstanding contributions to analytical chemistry and applied ... the world’s leading conference and exposition for laboratory science, which will be held ...
(Date:10/9/2017)... ... October 09, 2017 , ... The Giving Tree Wellness Center ... the needs of consumers who are incorporating medical marijuana into their wellness and ... , As operators of two successful Valley dispensaries, The Giving Tree’s two founders, ...
(Date:10/7/2017)... 6, 2017  The 2017 Nobel Prize in ... Jacques Dubochet, Joachim Frank and ... cryo-electron microscopy (cryo-EM) have helped to broaden ... biology community. The winners worked with systems manufactured ... produce highly resolved, three-dimensional images of protein structures ...
Breaking Biology Technology:
(Date:4/18/2017)... Calif. , April 18, 2017  Socionext Inc., a global ... of a media edge server, the M820, which features the company,s ... recognition software provided by Tera Probe, Inc., will be showcased during ... at the NAB show at the Las Vegas ... ...
(Date:4/11/2017)... April 11, 2017 Crossmatch®, a globally-recognized ... solutions, today announced that it has been awarded ... Projects Activity (IARPA) to develop next-generation Presentation Attack ... "Innovation has been a driving force within ... will allow us to innovate and develop new ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), Biometrics, Card-Based ... & Logistics, Government & Public Sector, Utilities / Energy ... Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality & ... for a definitive report on the $27.9bn Access Control ... ...
Breaking Biology News(10 mins):